Marksans Pharma gains on getting USFDA`s final approval for Famotidine Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Marksans Pharma is currently trading at Rs. 68.34, up by 0.65 points or 0.96% from its previous closing of Rs. 67.69 on the BSE.
The scrip opened at Rs. 66.11 and has touched a high and low of Rs. 69.00 and Rs. 66.00 respectively. So far 183263 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 72.25 on 22-Feb-2023 and a 52 week low of Rs. 38.70 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 69.47 and Rs. 66.00 respectively. The current market cap of the company is Rs. 3090.12 crore.
The promoters holding in the company stood at 49.00%, while Institutions and Non-Institutions held 5.20% and 45.80% respectively.
Marksans Pharma has received final approval from US Food & Drugs Administration (USFDA) for its Abbreviated New Drug Application (ANDA) of Famotidine Tablets USP, 10 mg and 20 mg for over-the-counter (OTC) use. The product is bioequivalent to the reference listed drug (RLD), Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer Inc. which has sales of over $200 million in the US market.
Marksans' OTC Famotidine Tablets USP, 10 mg and 20 mg, are acid reducers which used to treat conditions where reduction of stomach acid is needed, such as acid indigestion, occasional heartburn, or sour stomach from eating or drinking certain foods or beverages.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
